Surf Wiki
Save to docs
general/5-benzofuranethanamines

From Surf Wiki (app.surf) — the open knowledge base

Darifenacin

Medication for urinary incontinence

Medication for urinary incontinence

| Drugs.com =

| elimination_half-life = 13 to 19 hours

Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010, the US rights were sold to Warner Chilcott for .

Adverse effects

Darifenacin should not be used in people with urinary retention. Anticholinergic agents, such as darifenacin, may also produce constipation and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment.

Medical uses

Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults. It may also be recommended with an alpha blocker to help provide symptomatic benefit for overactive bladder and obstructive symptoms such as those likely associated with benign prostatic hyperplasia.

Mechanism of action

Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

References

References

  1. (2004). "Darifenacin: in the treatment of overactive bladder". Drugs & Aging.
  2. (July 2005). "Darifenacin in the treatment of overactive bladder". International Journal of Clinical Practice.
  3. (2008). "Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin". Clinical Interventions in Aging.
  4. (24 September 2016). "Enablex- darifenacin tablet, extended release".
  5. American Urological Association (AUA) Guideline. Diagnosis and Treatment of Overactive Bladder in Adults: AUA/SUFA guideline 2012
  6. (November 2004). "Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder". Expert Opinion on Investigational Drugs.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

5-benzofuranethanamines benzhydryl-compounds carboxamides cyp2d6-inhibitors drugs-developed-by-abbvie drugs-developed-by-novartis herg-blocker m1-receptor-antagonists m2-receptor-antagonists m3-receptor-antagonists m4-receptor-antagonists m5-receptor-antagonists phenylethylpyrrolidines
Want to explore this topic further?

Ask Mako anything about Darifenacin — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report